Blood pressure drug telmisartan may enhance PARP inhibitor olaparib beyond BRCA tumours
Preclinical research finds that combining telmisartan with olaparib boosts anticancer and immune effects, potentially broadening the PARP inhibitor's utility beyond BRCA1/2-related cancers, with human trials already under way.
Researchers have reported preclinical evidence that telmisartan — an angiotensin II receptor blocker widely used to treat hypertension — can significantly enhance the efficacy of olaparib, a PARP inhibitor currently approved for cancers associated with germline or somatic BRCA1/2 mutations. The findings, reported via ScienceDaily on 11 July 2026, suggest the combination produces both immune-boosting and direct anticancer effects in laboratory and animal models that exceed those seen with either agent alone.
Olaparib works by exploiting defective DNA damage repair in BRCA-mutated tumour cells through a mechanism known as synthetic lethality. The new research indicates that telmisartan may sensitise tumour cells that do not carry BRCA mutations to similar DNA-repair stress, potentially expanding the population of patients for whom PARP inhibition might be relevant — though this hypothesis requires validation in clinical trials.
The researchers note that human clinical trials combining the two drugs are already under way, which elevates the translational interest of this preclinical work. The institution responsible for the research, the specific journal, and the full trial registration details were not available in the feed summary; readers with a clinical or research interest are directed to ClinicalTrials.gov and the primary publication for complete methodological and trial-design information.
For oncologists and cancer geneticists, the findings are noteworthy in the context of ongoing efforts to extend the benefits of PARP inhibition to tumours with homologous recombination deficiency beyond canonical BRCA1/2 loss-of-function variants.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Scientists have published laboratory research suggesting that a common blood pressure medicine called telmisartan may help a cancer drug called olaparib work better. Olaparib is currently used mainly for cancers linked to faults in genes called BRCA1 and BRCA2, which affect how cells repair their DNA. The new research, carried out in laboratory and animal studies, suggests that combining the two drugs might make the cancer treatment more powerful — and possibly useful for more types of cancer, not just those with BRCA faults.
Researchers say that human clinical trials testing this combination are already running, which means scientists are actively studying whether these early results translate to people. This is an early-stage finding, and it is not yet known how the combination will perform in clinical trials.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-07-11Common blood pressure drug could make cancer therapy far more powerful